Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy

Current Molecular Medicine

Volumn 12, Issue 2, 2012, Pages 163-176

  Zhang, G ^a   Wang, Y ^b   Zhang, Y ^c   Wan, X ^d   Li, J ^e   Liu, K ^a   Wang, F ^f   Liu, Q ^a   Yang, C ^g   Yu, P ^a   Huang, Y ^a   Wang, S ^a   Jiang, P ^b   Qu, Z ^b   Luan, J ^a   Duan, H ^a   Zhang, L ^e   Hou, A ^h   Jin, S ^e   Hsieh, T C ⁱ   Wu, E ^f   more..

^a YANTAI UNIVERSITY   (China)

^b The 107 Hospital of Chinese PLA   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d ANHUI AGRICULTURAL UNIVERSITY   (China)

^e YANTAI YUHUANGDING HOSPITAL   (China)

^f NORTH DAKOTA STATE UNIVERSITY   (United States)

^g HARVARD UNIVERSITY   (United States)

^h Yantai Hospital of Traditional Chinese Medicine   (China)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

radiation; Adjuvant therapy; Breast cancer patients; EGCG; HGF; MMP9 MMP2; VEGF

Indexed keywords

EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN;

ADULT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; TEA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CATECHIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MET; TEA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862942636     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412798889063     Document Type: Article

References (63)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-36.
2. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40(1): 43-68.
3. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993; 85(22): 1819-27.
4. Wu AH, Yu MC, Tseng CC, Hankin J, Pike MC. Green tea and risk of breast cancer in Asian Americans. Int J Cancer 2003; 106(4): 574-9.
5. Zhang M, Holman CD, Huang JP, Xie X. Green tea and the prevention of breast cancer: a case-control study in Southeast China. Carcinogenesis 2007; 28(5): 1074-8.
6. Zhang G, Miura Y, Yagasaki K. Effects of green, oolong and black teas and related components on the proliferation and invasion of hepatoma cells in culture. Cytotechnology 1999; 31(1-2): 37-44.
7. Zhang G, Miura Y, Yagasaki K. Induction of apoptosis and cell cycle arrest in cancer cells by in vivo metabolites of teas. Nutr Cancer 2000; 38(2): 265-73.
8. Zhang G, Miura Y, Yagasaki K. Suppression of adhesion and invasion of hepatoma cells in culture by tea compounds through antioxidative activity. Cancer Lett 2000; 159(2): 169-73.
9. Yang CS. Inhibition of carcinogenesis by tea. Nature 1997; 389(6647): 134-5.
10. Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS. Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res 2006; 66(23): 11494-501.
11. Lu YP, Lou YR, Xie JG, et al. Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci USA 2002; 99(19): 12455-60.
12. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 2007; 245(1-2): 232-41.
13. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004; 64(23): 8715-22.
14. Wang ZY, Huang MT, Ho CT, et al. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 1992; 52(23): 6657-65.
15. Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R, Albini A. Tumor invasion: molecular shears blunted by green tea. Nat Med 1999; 5(11): 1216.
16. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 2001; 91(4): 822-32.
17. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89(24): 1881-6.
18. Sazuka M, Murakami S, Isemura M, Satoh K, Nukiwa T. Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. Cancer Lett 1995; 98(1): 27-31.
19. Taniguchi S, Fujiki H, Kobayashi H, et al. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett. 1992; 65(1): 51-4.
20. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999; 398(6726): 381.
21. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nature Rev 2009; 9(6): 429-39.
22. Rodriguez SK, Guo W, Liu L, Band MA, Paulson EK, Meydani M. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int J Cancer 2006; 118(7): 1635-44.
23. Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2002; 2(6): 350-9.
24. Sartippour MR, Shao ZM, Heber D, et al. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr 2002; 132(8): 2307-11.
25. Bigelow RL, Cardelli JA. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 2006; 25(13): 1922-30.
26. Vayalil PK, Katiyar SK. Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and-9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells. The Prostate 2004; 59(1): 33-42.
27. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998; 7(4): 351-4.
28. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9(9): 3312-9.
29. Chow HH, Hakim IA, Vining DR, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 2005; 11(12): 4627-33.
30. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12(3-4): 303-24.
31. Taichman NS, Young S, Cruchley AT, Taylor P, Paleolog E. Human neutrophils secrete vascular endothelial growth factor. J Leukocyte Biol 1997; 62(3): 397-400.
32. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3(12 Pt 1): 2187-90.
33. Lowery AJ, Sweeney KJ, Molloy AP, Hennessy E, Curran C, Kerin MJ. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer. BMC Cancer 2008; 8: 279.
34. Jing J, Zhao YB, Li HJ, Lu Q. Change and clinic significance of serum VEGF level before and after breast cancer patients treated. Sichuan da xue xue bao Yi xue ban 2006; 37(6): 889-92.
35. Tang JH, Zhao JH, Gong JP, Qin JW, Pan LQ, Xu ZY. Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer. Zhonghua Zhong Liu Za Zhi 2007; 29(3): 210-4.
36. Sheen-Chen SM, Liu YW, Eng HL, Chou FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14(3): 715-7.
37. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995; 1(9): 1031-4.
38. Toi M, Taniguchi T, Ueno T, et al. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 1998; 4(3): 659-64.
39. Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol 2007; 28(1): 36-44.
40. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004; 90(7): 1414-21.
41. Quaranta M, Daniele A, Coviello M, et al. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res 2007; 27(5B): 3593-600.
42. Viatour P, Bentires-Alj M, Chariot A, et al. NF-kappa B2/p100 induces Bcl-2 expression. Leukemia 2003; 17(7): 1349-56.
43. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292(5517): 727-30.
44. Marsden VS, O'Connor L, O'Reilly LA, et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419(6907): 634-7.
45. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999; 19(7): 4798-805.
46. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401(6748): 82-5.
47. Wang CY, Mayo MW, Baldwin AS, Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science. 1996; 274(5288): 784-7.
48. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002; 27(9): 462-7.
49. Patel JB, Mehta J, Belosay A, et al. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer 2007; 96(8): 1204-15.
50. Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factorkappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002; 21(23): 3727-38.
51. Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005; 7(6): R940-52.
52. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6(3): 203-8.
53. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004; 10(1 Pt 1): 202-11.
54. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437(7058): 497-504.
55. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001; 98(22): 12485-90.
56. Gupta VK, Jaskowiak NT, Beckett MA, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer journal 2002; 8(1): 47-54.
57. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68(1): 152-61.
58. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 2000; 78(3): 465-75.
59. Suzuki M, Mose E, Galloy C, Tarin D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 2007; 171(2): 682-92.
60. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev Cancer 2002; 2(4): 289-300.
61. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003; 100(22): 12718-23.
62. Kunigal S, Lakka SS, Joseph P, Estes N, Rao JS. Matrix metalloproteinase-9 inhibition down-regulates radiationinduced nuclear factor-kappa B activity leading to apoptosis in breast tumors. Clin Cancer Res 2008; 14(11): 3617-26.
63. Chen D, Wang CY, Lambert JD, Ai N, Welsh WJ, Yang CS. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol 2005; 69(10): 1523-31.